Evidence map›Paper›PMID 41306978›Full record

ArticleFrontiers in immunology2025

Mitogen-activated protein kinase pathway and four genes involved in the development of benign prostatic hyperplasia:

Jia-Min Gu, Xing-Pei Guo, Lan Wu, Lu-Yao Li, Cong Zhu, Tong Deng, Shuang-Ying Wang, Cheng Fang, Xian-Tao Zeng

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jia-Min GuDepartment of Urology, Institute of Urology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Xing-Pei GuoCenter for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Lan WuCenter for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Lu-Yao LiCenter for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Cong ZhuDepartment of Urology, Institute of Urology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Tong DengCenter for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Shuang-Ying WangCenter for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Cheng FangCenter for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Xian-Tao ZengDepartment of Urology, Institute of Urology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Benign prostatic hyperplasia (BPH) is a common age-associated disorder characterized by non-malignant proliferation of prostate tissues. However, its underlying molecular mechanisms remain incompletely elucidated. Methods: A rat model of BPH was established via surgical castration followed by testosterone propionate administration. Proteomic profiling was performed on prostate tissues from BPH and sham-operated rats. Public datasets of BPH patients and healthy individuals were also analyzed to validate the translational relevance. In addition, qPCR was conducted on both rat tissues and human-derived prostate cell lines to confirm gene expression levels. Furthermore, immunohistochemistry was performed on prostate tissue samples from BPH patients to examine the expression and localization of the target proteins. Results: Proteomic analysis revealed significant upregulation of four proteins-QPCT, ARHGEF37, FLNC, and LGALS7-in BPH model rats compared with controls. KEGG pathway enrichment identified the MAPK signaling pathway as a potential key regulator of BPH progression. Similar expression patterns were observed in human datasets. qPCR results further validated the elevated expression of these four genes in both rat and human BPH-related samples. Immunohistochemistry further demonstrated that all four proteins were highly expressed in prostate tissues from BPH patients. Conclusions: The aberrant overexpression of QPCT, ARHGEF37, FLNC, and LGALS7, along with dysregulation of the MAPK signaling pathway, may contribute to BPH pathogenesis. These findings provide new insights into the molecular mechanisms of BPH and may inform the development of diagnostic markers or therapeutic targets.

Indexed as

MAP Kinase Signaling SystemProstatic HyperplasiaAgedAnimalsDisease Models, AnimalGalectinsHumansMaleProstateProteomicsRatsRats, Sprague-DawleyGalectinsbenign prostatic hyperplasiagenetic markersimmunologyMAPK pathwayproteomics

Identifiers

PMID41306978
PMCPMC12644057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.